Netradyne | $90,000,000 | (Jan 17, 2025)
Truewind | $13,000,000 | (Jan 17, 2025)
Peregrine Health | $5,000,000 | (Jan 17, 2025)
Certified by Founder
Lodge
Corsair Pharma
start up
United States
- Sunnyvale, California
- 22/09/2023
- Series B
- $23,000,000
Corsair Pharma is developing transformative solutions to improve the therapeutic profile of medications and provide superior treatment options for patients. The company is focused on the development of novel prodrugs of treprostinil to treat patients with PAH using a once-daily transdermal patch.
- Industry Pharmaceutical Manufacturing
- Website https://www.corsairpharma.com/
- LinkedIn https://www.linkedin.com/company/corsairpharma/about/
Guidesly | $9,500,000 | (Jan 17, 2025)
Alium | $7,000,000 | (Jan 17, 2025)
Pipe17 | $15,500,000 | (Jan 17, 2025)
Coram AI | $13,800,000 | (Jan 17, 2025)
Quantifind | $22,000,000 | (Jan 17, 2025)
Hyperline | $10,000,000 | (Jan 17, 2025)
Origen | $13,000,000 | (Jan 17, 2025)
Komainu | $75,000,000 | (Jan 17, 2025)
Hinge Bio | $30,000,000 | (Jan 16, 2025)